HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.

Abstract
Histone deacetylases are considered to be among the most promising targets in drug development for cancer therapy. Histone deacetylase 6 (HDAC6) is a unique cytoplasmic enzyme that regulates many biological processes involved in tumorigenesis through its deacetylase and ubiquitin-binding activities. Here, we report that HDAC6 is overexpressed in glioblastoma tissues and cell lines. Overexpression of HDAC6 promotes the proliferation and spheroid formation of glioblastoma cells. HDAC6 overexpression confers resistance to temozolomide (TMZ) mediated cell proliferation inhibition and apoptosis induction. Conversely, knockdown of HDAC6 inhibits cell proliferation, impairs spheroid formation and sensitizes glioblastoma cells to TMZ. The inhibition of HDAC6 deacetylase activity by selective inhibitors inhibits the proliferation of glioblastoma cells and induces apoptosis. HDAC6 selective inhibitors can sensitize glioblastoma cells to TMZ. Moreover, we showed that HDAC6 mediated EGFR stabilization might partly account for its oncogenic role in glioblastoma. TMZ resistant glioblastoma cells showed higher expression of HDAC6 and more activation of EGFR. HDAC6 inhibitors decrease EGFR protein levels and impair the activation of the EGFR pathway. Taken together, our results suggest that the inhibition of HDAC6 may be a promising strategy for the treatment of glioblastoma.
AuthorsZhihao Wang, Pengchao Hu, Fang Tang, Haiwei Lian, Xiong Chen, Yingying Zhang, Xiaohua He, Wanhong Liu, Conghua Xie
JournalCancer letters (Cancer Lett) Vol. 379 Issue 1 Pg. 134-42 (08 28 2016) ISSN: 1872-7980 [Electronic] Ireland
PMID27267806 (Publication Type: Journal Article)
CopyrightCopyright © 2016 Elsevier Ireland Ltd. All rights reserved.
Chemical References
  • Antineoplastic Agents, Alkylating
  • Histone Deacetylase Inhibitors
  • Dacarbazine
  • EGFR protein, human
  • ErbB Receptors
  • HDAC6 protein, human
  • Histone Deacetylase 6
  • Histone Deacetylases
  • Temozolomide
Topics
  • Antineoplastic Agents, Alkylating (pharmacology)
  • Apoptosis (drug effects)
  • Brain Neoplasms (drug therapy, enzymology, genetics, pathology)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Dacarbazine (analogs & derivatives, pharmacology)
  • Dose-Response Relationship, Drug
  • Drug Resistance, Neoplasm (drug effects)
  • ErbB Receptors (drug effects, metabolism)
  • Glioblastoma (drug therapy, enzymology, genetics, pathology)
  • Histone Deacetylase 6
  • Histone Deacetylase Inhibitors (pharmacology)
  • Histone Deacetylases (genetics, metabolism)
  • Humans
  • Protein Stability
  • Signal Transduction (drug effects)
  • Temozolomide
  • Time Factors
  • Transfection
  • Up-Regulation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: